STOCK TITAN
  1. Home
  2. News
  3. ZVRA

Zevra Therapeutics Inc - ZVRA STOCK NEWS

Welcome to our dedicated news page for Zevra Therapeutics (Ticker: ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zevra Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zevra Therapeutics's position in the market.

News
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
Rhea-AI Summary
Zevra Therapeutics presents new data on the long-term safety and efficacy of Arimoclomol as a treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
-
News
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
Rhea-AI Summary
Zevra Therapeutics, Inc. secures a new $100M credit facility led by Perceptive Advisors and Healthcare Royalty to support its rare disease therapeutics development. The facility includes an initial draw of $60M, with additional tranches available upon meeting certain conditions. Zevra retires existing debt of $43.1M, with net proceeds of $14.0M. The five-year facility bears interest at 12.33% per annum and allows in-kind interest payments. This move aims to strengthen Zevra's financial position and advance its strategic goals for 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags
none
-
News
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
Rhea-AI Summary
Zevra Therapeutics, Inc. reports strong financial results for Q4 2023 with a net revenue of $13.2M and FY 2023 net revenue of $27.5M. The company made progress in launching OLPRUVA® and preparing for arimoclomol launch. Positive data from the KP1077 phase 2 study in idiopathic hypersomnia was highlighted. The company completed the acquisition of Acer Therapeutics, Inc., enhancing its rare disease assets and revenue potential. Financially, there was an increase in net revenue, but also an increase in R&D and G&A expenses, leading to a net loss for both Q4 and FY 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.03%
Tags
earnings
News
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
Rhea-AI Summary
Zevra Therapeutics, Inc. announces positive top-line data from its Phase 2 clinical trial evaluating KP1077 for idiopathic hypersomnia, showing clinically meaningful benefits for key symptoms. The study demonstrated improvements in excessive daytime sleepiness, sleep inertia, and brain fog, supporting the safety and tolerability of KP1077 for further development into a Phase 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
clinical trial
-
News
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Zevra Therapeutics, Inc. (ZVRA) to participate in the 23rd Annual Needham Virtual Healthcare Conference. Presentation scheduled for April 8, 2024, at 3:45 p.m. ET. Management team available for one-on-one investor meetings. Webcast and archived presentation details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
conferences
-
News
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024
Rhea-AI Summary
Zevra Therapeutics, Inc. to host a conference call to discuss corporate and financial results for Q4 and full year 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences earnings
News
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
Rhea-AI Summary
Zevra Therapeutics, Inc. announces FDA extension of arimoclomol NDA review for Niemann-Pick disease type C with a new PDUFA action date of September 21, 2024. The company remains optimistic about the potential of arimoclomol to help patients despite the delay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.15%
Tags
none
-
News
Zevra Therapeutics to Participate at Upcoming Investor Conferences
Rhea-AI Summary
Zevra Therapeutics, Inc. (ZVRA) announces Neil F. McFarlane, President and CEO, will present at investor conferences in March 2024. The company will participate in TD Cowen 44th Annual Health Care Conference and 36th Annual ROTH Conference. The live webcasts will be available on Zevra's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
conferences
-
News
Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Zevra Therapeutics, Inc. (ZVRA) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The company's management team will also be available for one-on-one investor meetings. The live webcast will be accessible on the company's website, and the archived presentation will be available thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
conferences
News
Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors
Rhea-AI Summary
Zevra Therapeutics, Inc. appoints Alvin Shih, MD, MBA, to its Board of Directors. Dr. Shih brings extensive experience in biotechnology leadership and rare disease therapeutics development. He has held leadership roles at various biotechnology companies and has a strong background in drug development for rare diseases. Zevra's Board and management team express confidence in Dr. Shih's ability to contribute to the advancement of the company's therapeutic portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
management
Stock ZVRA logo
Zevra Therapeutics Inc

Nasdaq:ZVRA

ZVRA Rankings

#3809 Ranked by Market Cap
#3480 Ranked by Stock Gains
N/A Ranked by Dividends

ZVRA Stock Data

200.88M
36.09M
8.08%
29.7%
5.38%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Celebration

About ZVRA

kempharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (nces) to treat serious medical conditions through its proprietary and broadly applicable ligand activated therapy (lat) approach. the company utilizes its lat technology to generate improved prodrug versions of fda approved drugs in the high needs areas of pain, adhd and other cns diseases.